Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT202 in Chinese participants with hypertriglyceridemia
CTR20253312Phase 2Active
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of JMT202 in hypertriglyceridemia, sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Sep 2025; status: active.
02
Drugs
JMT202
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on CTR20253312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253312.